BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38142057)

  • 41. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
    Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
    Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
    Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
    J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
    Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
    Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
    Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
    Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
    Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BAP1 GERMLINE MUTATION WITH IRIDOCILIOCHOROIDAL MELANOMA AND MALIGNANT PERITONEAL MESOTHELIOMA.
    Yaghy A; Lim LA; Mashayekhi A; Shields CL
    Retin Cases Brief Rep; 2022 Mar; 16(2):194-198. PubMed ID: 31895725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
    Hakiri S; Osada H; Ishiguro F; Murakami H; Murakami-Tonami Y; Yokoi K; Sekido Y
    Cancer Sci; 2015 Aug; 106(8):990-9. PubMed ID: 26011428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
    Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S
    Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
    Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
    Carbone M; Pass HI; Ak G; Alexander HR; Baas P; Baumann F; Blakely AM; Bueno R; Bzura A; Cardillo G; Churpek JE; Dianzani I; De Rienzo A; Emi M; Emri S; Felley-Bosco E; Fennell DA; Flores RM; Grosso F; Hayward NK; Hesdorffer M; Hoang CD; Johansson PA; Kindler HL; Kittaneh M; Krausz T; Mansfield A; Metintas M; Minaai M; Mutti L; Nielsen M; O'Byrne K; Opitz I; Pastorino S; Pentimalli F; de Perrot M; Pritchard A; Ripley RT; Robinson B; Rusch V; Taioli E; Takinishi Y; Tanji M; Tsao AS; Tuncer AM; Walpole S; Wolf A; Yang H; Yoshikawa Y; Zolondick A; Schrump DS; Hassan R
    J Thorac Oncol; 2022 Jul; 17(7):873-889. PubMed ID: 35462085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
    Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
    Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Malignant mesothelioma in situ: diagnostic and clinical considerations.
    Pulford E; Henderson DW; Klebe S
    Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
    Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
    Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of second primary cancers after malignant mesothelioma and vice versa.
    Chen T; Kharazmi E; Lou J; Zhang X; Sundquist K; Hemminki K
    Cancer Lett; 2016 Aug; 379(1):94-9. PubMed ID: 27260871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
    Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
    Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
    Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
    Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A case of malignant peritoneal mesothelioma].
    Zhao F; Zhang YL; Liu X; Chen TH; Li J
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Apr; 41(4):307-309. PubMed ID: 37248188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A Case of Malignant Peritoneal Mesothelioma Treated with Cisplatin and Pemetrexed].
    Sone T; Omori S; Hayashi K; Yamato H; Ohira K; Kondo N; Takagi Y; Kato K
    Gan To Kagaku Ryoho; 2018 Jun; 45(6):993-995. PubMed ID: 30026430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.